Fulcrum Therapeutics (NasdaqGM:FULC) Earnings Call Presentation

Pociredir PIONEER Study: 20 mg Cohort ASH Data Release December 7, 2025 Disclaimer and Notice This presentation contains "forward-looking statements" of Fulcrum Therapeutics, Inc. (Fulcrum or Fulcrum Therapeutics) within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including express or implied statements regarding regarding the significance of initial results from the 20 mg cohort, Fulcrum's goals for pociredir, pociredir's best-in-cla ...